Drug intelligence / Profile preview

Deuterated 3-methylhistidine

Development stage
Preclinical
Lead developer
Cambridge Isotope Laboratories
Modality
Small Molecules
Administration
Intravenous, Oral
01

Overview

Deuterated 3-methylhistidine is a stable isotope-labeled derivative of the amino acid histidine in which three hydrogen atoms are replaced by deuterium. It is primarily used as a diagnostic and research tool rather than as a therapeutic drug. Upon administration, deuterated 3-methylhistidine is incorporated into muscle proteins (specifically actin and myosin) and subsequently excreted unchanged in urine. This property allows it to serve as a tracer for measuring skeletal muscle protein breakdown and turnover rates in vivo. The compound is widely used in metabolic studies to assess muscle protein catabolism by tracking its appearance in biological samples such as urine or plasma[1][2][4][5]. It does not have direct pharmacological activity but serves an important role as an internal standard or biomarker for quantifying endogenous 3-methylhistidine levels during analytical procedures[4][8].

Other names
3-Methyl-L-histidine-d3d₃-3-methylhistidine
02

Targets

Skeletal muscle myosin (SkM-Myosin)Actin filament proteins

Beyond the preview

Go deeper on Deuterated 3-methylhistidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deuterated 3-methylhistidine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call